These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20448107)

  • 1. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.
    Waage A; Gimsing P; Fayers P; Abildgaard N; Ahlberg L; Björkstrand B; Carlson K; Dahl IM; Forsberg K; Gulbrandsen N; Haukås E; Hjertner O; Hjorth M; Karlsson T; Knudsen LM; Nielsen JL; Linder O; Mellqvist UH; Nesthus I; Rolke J; Strandberg M; Sørbø JH; Wisløff F; Juliusson G; Turesson I;
    Blood; 2010 Sep; 116(9):1405-12. PubMed ID: 20448107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M; Haznedar R; Firatli-Tuglular T; Ozdogu H; Aydogdu I; Konuk N; Sucak G; Kaygusuz I; Karakus S; Kaya E; Ali R; Gulbas Z; Ozet G; Goker H; Undar L
    Eur J Haematol; 2011 Jan; 86(1):16-22. PubMed ID: 20942865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
    Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M;
    Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
    Palumbo A; Bringhen S; Liberati AM; Caravita T; Falcone A; Callea V; Montanaro M; Ria R; Capaldi A; Zambello R; Benevolo G; Derudas D; Dore F; Cavallo F; Gay F; Falco P; Ciccone G; Musto P; Cavo M; Boccadoro M
    Blood; 2008 Oct; 112(8):3107-14. PubMed ID: 18505783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
    Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
    Lancet; 2007 Oct; 370(9594):1209-18. PubMed ID: 17920916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.
    Stewart AK; Jacobus S; Fonseca R; Weiss M; Callander NS; Chanan-Khan AA; Rajkumar SV
    Blood; 2015 Sep; 126(11):1294-301. PubMed ID: 26157076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
    Kapoor P; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Mikhael JR; Roy V; Kyle RA; Greipp PR; Kumar S; Mandrekar SJ
    Leukemia; 2011 Apr; 25(4):689-96. PubMed ID: 21233832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
    Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
    Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
    Sacchi S; Marcheselli R; Lazzaro A; Morabito F; Fragasso A; Di Renzo N; Balleari E; Neri S; Quarta G; Ferrara R; Vigliotti ML; Polimeno G; Musto P; Consoli U; Zoboli A; Buda G; Pastorini A; Masini L
    Leuk Lymphoma; 2011 Oct; 52(10):1942-8. PubMed ID: 21663513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
    Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
    Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
    Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
    Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
    Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
    N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
    Wijermans P; Schaafsma M; Termorshuizen F; Ammerlaan R; Wittebol S; Sinnige H; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst H; Sonneveld P;
    J Clin Oncol; 2010 Jul; 28(19):3160-6. PubMed ID: 20516439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.
    Hulin C; Belch A; Shustik C; Petrucci MT; Dührsen U; Lu J; Song K; Rodon P; Pégourié B; Garderet L; Hunter H; Azais I; Eek R; Gisslinger H; Macro M; Dakhil S; Goncalves C; LeBlanc R; Romeril K; Royer B; Doyen C; Leleu X; Offner F; Leupin N; Houck V; Chen G; Ervin-Haynes A; Dimopoulos MA; Facon T
    J Clin Oncol; 2016 Oct; 34(30):3609-3617. PubMed ID: 27325857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
    Lokhorst HM; van der Holt B; Zweegman S; Vellenga E; Croockewit S; van Oers MH; von dem Borne P; Wijermans P; Schaafsma R; de Weerdt O; Wittebol S; Delforge M; Berenschot H; Bos GM; Jie KS; Sinnige H; van Marwijk-Kooy M; Joosten P; Minnema MC; van Ammerlaan R; Sonneveld P;
    Blood; 2010 Feb; 115(6):1113-20. PubMed ID: 19880501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma--a retrospective population based study of 1162 patients.
    Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
    Eur J Haematol; 2014 Jan; 92(1):19-25. PubMed ID: 24118547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review.
    Kumar A; Hozo I; Wheatley K; Djulbegovic B
    Am J Hematol; 2011 Jan; 86(1):18-24. PubMed ID: 21120867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.